S.F. biotech inches closer to potential HIV cure with key move by FDA


Using the CRISPR genome-editing technology that won UC Berkeley's Jennifer Doudna a share of the 2020 Nobel Prize in chemistry, the company has a potential cure for HIV in an early-stage clinical trial.

Previous Fire Awards 2023: Sentio Biosciences brings new drug to market, works on another while expanding operations
Next Cornerstone Hospice debuts Orange County's first standalone hospice house